MVA BN nef

Drug Profile

MVA BN nef

Alternative Names: HIV nef vaccine - Bavarian Nordic; MVA nef; MVA HIV nef; MVA-BN nef

Latest Information Update: 12 Nov 2007

Price : $50

At a glance

  • Originator Bavarian Nordic
  • Class AIDS vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued HIV infections

Most Recent Events

  • 06 Nov 2007 Discontinued - Phase-II for HIV infections treatment in Germany (SC)
  • 13 Mar 2007 Data presented at the 14th Conference on Retroviruses and Opportunistic Infections (CROI-2007) have been added to the adverse events and Viral infections therapeutic trials sections
  • 27 Dec 2006 Interim results from a phase II trial in HIV-infected patients added to the Viral Infections therapeutic trials section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top